The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! About 6.27M shares traded hands or 497.14% up from the average. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 566.67% since April 8, 2016 and is uptrending. It has outperformed by 561.02% the S&P500.
The move comes after 6 months positive chart setup for the $68.60 million company. It was reported on Nov, 10 by Barchart.com. We have $7.45 PT which if reached, will make NASDAQ:EBIO worth $130.34 million more.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) earned “Neutral” rating by Citigroup on Tuesday, January 19. The stock has “Outperform” rating given by Leerink Swann on Saturday, August 15. The stock has “Market Perform” rating given by Leerink Swann on Tuesday, January 19. The stock has “Neutral” rating given by Citigroup on Wednesday, March 16.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.62, from 0.38 in 2016Q1. The ratio improved, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
Grp One Trading Ltd Partnership accumulated 0% or 600 shares. Royal State Bank Of Canada holds 0% or 500 shares in its portfolio. Guggenheim Capital Lc reported 10,331 shares or 0% of all its holdings. Fincl Bank Of New York Mellon reported 67,483 shares or 0% of all its holdings. Kcg Holding Incorporated has invested 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Goldman Sachs Incorporated holds 13,343 shares or 0% of its portfolio. Fiduciary Co accumulated 10,000 shares or 0% of the stock. Morgan Stanley has 1,503 shares for 0% of their US portfolio. Renaissance Tech Ltd Liability last reported 118,500 shares in the company. Blackrock Institutional Tru Na accumulated 149,618 shares or 0% of the stock. Flagship Ventures 2007 General Partner Limited Liability Corporation has invested 2.98% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Two Sigma Ltd Liability Corporation holds 0.02% or 25,428 shares in its portfolio. Vanguard Gru last reported 0% of its portfolio in the stock. Fincl Bank Of America De holds 0% or 35 shares in its portfolio. Moreover, Geode Capital Limited Co has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 46,637 shares.
More news for Eleven Biotherapeutics Inc (NASDAQ:EBIO) were recently published by: Marketwatch.com, which released: “Eleven Biotherapeutics stock up 25% on news of Viventia Bio purchase” on September 21, 2016. 247Wallst.com‘s article titled: “Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?” and published on August 16, 2016 is yet another important article.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.